drugset / Trial / NCT05477589

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

NCT05477589

Phase 3 Recruiting 170 enrolled Vastra Gotaland Region
RandomizedFactorialOpen-labelTreatment

Summary

It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)

Timeline

Start
2022-06-07
Primary completion
2029-12-31
Completion
2031-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified
Comparator Cyclophosphamide Other / unclassified
Subject Fludarabine Small molecule
Comparator Melphalan Small molecule
Background Busulfan Small molecule